|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
We retrospectively assessed metabolic parameters, the body habitus, and other health-related parameters of 48 patients with surgically controlled acromegaly who met the Cortina criteria [normalized insulin-like growth factor-1 (IGF-1) level and nadir growth hormone (GH) level <1.0 ng/ml during postoperative oral glucose tolerance test].
|
29479042 |
2018 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The objective of this study was to investigate the effect of hyperprolactinemia and high levels of insulin-like growth factor-I (IGF-I) on bone resorption and their relation with receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin (OPG) in patients with prolactinoma and acromegaly.
|
29895074 |
2018 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Body mass index and percentage of upper limit of normal range IGF-1 before TSA might constitute prognostic risk factors for discordance in IGF-1 and GH levels in acromegaly.
|
28341329 |
2018 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
IGF-1 independently correlates with the coronary microvascular impairment, suggesting the pivotal role of this hormone in explaining the increased cardiovascular risk in acromegaly.
|
29353224 |
2018 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
The high proliferative, but absence of non-proliferative retinopathy in our patients with acromegaly may reflect the pathogenic effect of IGF-1 on neovascularization.
|
29198552 |
2018 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Among those with persistent disease following surgery, a normal insulin-like growth factor 1 (IGF-1) was achieved in 52% (61/117), with a median time to acromegaly control of 4.5 years.
|
30048170 |
2018 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Discordant GH and IGF-I values are frequent in acromegaly.
|
28993415 |
2018 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
We suggest IGF-1 monitoring in all patients treated with dopamine agonists and not only in those presenting symptoms of acromegaly.
|
29728863 |
2018 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PAS-LAR normalizes IGF-I levels in most acromegaly patients, with a fifty percent pegvisomant-sparing effect.
|
30076159 |
2018 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The combination of growth hormone (GH) nadir during the oral glucose tolerance test (OGTT) and elevated insulin-like growth factor-1 (IGF-1) levels was used by 99 physicians (63.9%) to diagnose acromegaly.
|
29971605 |
2018 |
|
Acromegaly
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Twenty-six patients with active acromegaly (IGF-I >130% upper limit of normal) were randomised to subcutaneous ATL1103 200 mg either once or twice weekly for 13 weeks and monitored for a further 8-week washout period.
|
29789410 |
2018 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This lack of association may suggest that tear IGF-1 levels might not have an effect on CCT or IOP findings in patients with acromegaly.
|
28127733 |
2017 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Cabergoline monotherapy is reported to normalize IGF-I levels in more than one-third of patients with acromegaly.
|
28025719 |
2017 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Control of acromegaly was defined as a random serum growth hormone (GH) < 1 ng/mL and an age-normalised serum insulin-like growth factor-I (IGF-I) value.
|
28879646 |
2017 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our data indicates that tissue-level properties of cortical bone are significantly altered in patients with controlled acromegaly after reversal of long-term exposure to pathologically high GH and IGF-1 levels.
|
28077497 |
2017 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Management of acromegaly is particularly challenging in cases where discordant information is obtained from measurement of GH concentrations following oral glucose load and from measurement of IGF-I.
|
28168377 |
2017 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Included in this prospective cohort were 41 patients with acromegaly who underwent surgery alone and achieved postoperative normalization of insulin-like growth factor-1.
|
27681883 |
2017 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
530 patients (36%) reported at least 1 acral enlargement symptom and were tested for IGF-1, 41 were above range, persisted in 7, and among those, 2 cases of acromegaly were diagnosed (prevalence of at least 1.35 cases/1000).
|
28898247 |
2017 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
A low secretory activity of these tumours might explain the normal plasma values for GH and insulin-like growth factor 1 (IGF1) and the absence of clinical signs of acromegaly.
|
27913611 |
2017 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
In principle, the fetal-placental collaboration between mother and child more-or-less takes over the control over GH and IGF-1, not only in normal physiology but also to a certain extend in acromegaly.
|
27568329 |
2017 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acromegaly is characterized by growth hormone (GH) and insulinlike growth factor-1 (IGF-1) hypersecretion, and GH and IGF-1 play important roles in regulating body composition and glucose homeostasis.
|
28945897 |
2017 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
The objectives of this study were to establish the probability and predictive factors for short- and long-term remission [normal IGF-1 for age/sex: IGF-1 ≤1.00 × upper limit of normal (ULN)] after octreotide long-acting release (LAR) withdrawal in a larger population of well-controlled patients with acromegaly (normal mean IGF-1 in the last 24 months).
|
27161443 |
2017 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acromegaly is a rare disease generally brought about by a benign tumour in the pituitary and characterized by growth hormone (GH) and insulin-like growth factor 1 (IGF-1) excess.
|
28808855 |
2017 |
|
Acromegaly
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Endocrine GH and IGF-1 were strongly upregulated without causing acromegaly.
|
28881863 |
2017 |
|
Acromegaly
|
0.400 |
Biomarker
|
disease |
BEFREE |
METHODS This retrospective analysis correlates 414 pairs of GH and IGF-1 values in 93 patients with acromegaly.
|
27858572 |
2017 |